LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article: Role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the management of atrial fibrillation.

    Anis, Rafik R

    Experimental and clinical cardiology

    2009  Volume 14, Issue 1, Page(s) e1–7

    Abstract: Atrial fibrillation (AF) is the most common clinical arrhythmia, and is difficult to treat. Current treatment strategies are far from optimal. Antiarrhythmic drug therapy to maintain sinus rhythm is limited by inadequate efficacy and potentially serious ... ...

    Abstract Atrial fibrillation (AF) is the most common clinical arrhythmia, and is difficult to treat. Current treatment strategies are far from optimal. Antiarrhythmic drug therapy to maintain sinus rhythm is limited by inadequate efficacy and potentially serious side effects. New areas of research include targeting the AF substrate and examining whether drugs can produce atrial structural and/or electrophysiological remodelling, and whether this results in a reduction in AF burden. There are two approaches to the treatment of AF. The first approach is cardioversion and treatment with antiarrhythmic drugs to maintain sinus rhythm. The other approach is the use of rate-controlling drugs allowing AF to persist. In both approaches, the use of anticoagulant drugs is recommended. There is an increasing interest in novel therapeutic approaches that target AF-substrate development. Recent trials suggest that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor II blockers (ARBs) may be useful, particularly in patients with left ventricular hypertrophy, hypertension, chronic heart failure and left ventricular dysfunction. While experimental studies have shown that the pathogenic structural and electrical remodelling of the atria are prevented by inhibition of angiotensin II, the clinical potential and mechanisms of this approach are still under active investigation. The present article will discuss information pertaining to the mechanism of action and clinical use of ACEIs and ARBs in AF. It will also review the current data on the use of ACEIs and ARBs in a high-risk group of AF patients (heart failure, hypertensive with left ventricular hypertrophy, and myocardial infarction), together with the potential benefit of this class type of pharmacological therapy in direct current cardioversion and after radiofrequency catheter ablation.
    Language English
    Publishing date 2009-04-07
    Publishing country Canada
    Document type Journal Article
    ZDB-ID 2061162-6
    ISSN 1205-6626
    ISSN 1205-6626
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6009: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: The Thermal and Mechanical Behaviour of Wood-PLA Composites Processed by Additive Manufacturing for Building Insulation.

    Bahar, Anis / Hamami, Ameur El Amine / Benmahiddine, Ferhat / Belhabib, Sofiane / Belarbi, Rafik / Guessasma, Sofiane

    Polymers

    2023  Volume 15, Issue 14

    Abstract: This study was aimed at considering the potential of wood-based composites processed using additive manufacturing as insulators in the building sector. A polylactic acid blend with 30% wood particles was used as a feedstock material in fused filament ... ...

    Abstract This study was aimed at considering the potential of wood-based composites processed using additive manufacturing as insulators in the building sector. A polylactic acid blend with 30% wood particles was used as a feedstock material in fused filament technology. Its thermal and mechanical properties were determined for various processing conditions, including printing temperature and infill rate. The results showed a minor contraction in its tensile performance as a result of the printing process. The printing temperature had a negligible effect on its stiffness and a limited influence on the other engineering constants, such as the tensile strength and ultimate stress. The thermal properties of printed structures have been found to significantly depend on the infill rate. Although the tested 3D printed wood-PLA material exhibited good thermal properties, which were tuneable using the printing conditions, its performance was still 38% to 57% lower compared to insulators such as the glass wool of the synthetic foams used in the building sector.
    Language English
    Publishing date 2023-07-16
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2527146-5
    ISSN 2073-4360 ; 2073-4360
    ISSN (online) 2073-4360
    ISSN 2073-4360
    DOI 10.3390/polym15143056
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: An update on clinical and pharmacological aspects of drug-eluting stents.

    Anis, Rafik R / Karsch, Karl R / Oberhoff, Martin

    Cardiovascular & hematological disorders drug targets

    2007  Volume 6, Issue 4, Page(s) 245–255

    Abstract: The introduction of stents to clinical practice was the major breakthrough in the field of percutaneous coronary intervention. The introduction of stents was associated with two serious complications, the first was increase in subacute thrombosis within ... ...

    Abstract The introduction of stents to clinical practice was the major breakthrough in the field of percutaneous coronary intervention. The introduction of stents was associated with two serious complications, the first was increase in subacute thrombosis within the first 30 days of stent implantation later controlled with the use of high pressure inflation and dual antiplatelet therapy, the second was the phenomenon of in-stent restenosis that was primarily caused by smooth muscle proliferation. While coronary stenting eliminates elastic recoil, it is unable to inhibit excessive neointimal formation. Stents were associated with an increase of neointimal formation compared to balloon angioplasty as a result of excessive injury to the vessel wall and the inflammatory process from interaction of metal with vessel wall. Local delivery of the potential agents for inhibition of neointimal formation to the site of the lesion was considered the desired approach. Several compounds have been tested for stent coating, primarily with the aim of the inhibition of SMC proliferation. Recently, new stents have emerged which are loaded with anti-inflammatory, anti-migratory, anti-proliferative or pro-healing drugs. In this review article the results of clinical studies investigating drug-eluting stents are discussed from pharmacological and clinical points of view, reviewing the current literature and the future prospective.
    MeSH term(s) Animals ; Anti-Inflammatory Agents, Non-Steroidal/administration & dosage ; Anti-Inflammatory Agents, Non-Steroidal/therapeutic use ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/therapeutic use ; Biocompatible Materials/adverse effects ; Cardiovascular Agents/administration & dosage ; Cardiovascular Agents/adverse effects ; Cardiovascular Agents/therapeutic use ; Clinical Trials as Topic ; Coronary Disease/surgery ; Coronary Disease/therapy ; Graft Occlusion, Vascular/prevention & control ; Humans ; Immunologic Factors/administration & dosage ; Immunologic Factors/therapeutic use ; Polymers ; Protease Inhibitors/administration & dosage ; Protease Inhibitors/therapeutic use ; Stents/adverse effects
    Chemical Substances Anti-Inflammatory Agents, Non-Steroidal ; Antineoplastic Agents ; Biocompatible Materials ; Cardiovascular Agents ; Immunologic Factors ; Polymers ; Protease Inhibitors
    Language English
    Publishing date 2007-03-20
    Publishing country United Arab Emirates
    Document type Journal Article ; Review
    ZDB-ID 2244164-5
    ISSN 2212-4063 ; 1871-529X
    ISSN (online) 2212-4063
    ISSN 1871-529X
    DOI 10.2174/187152906779010755
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5610: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Coronary collateral circulation: effect on early and midterm outcomes after off-pump coronary artery bypass surgery.

    Caputo, Massimo / Anis, Rafik R / Rogers, Chris A / Ahmad, Nazir / Rizvi, Syed I A / Baumbach, Andreas / Karsch, Karl R / Angelini, Gianni D / Oberhoff, Martin

    The Annals of thoracic surgery

    2008  Volume 85, Issue 1, Page(s) 71–79

    Abstract: Background: The purpose of this study was to assess the prognostic effect of coronary collaterals on early and midterm clinical outcomes in patients undergoing first time isolated off-pump coronary artery bypass (OPCAB) surgery.: Methods: ... ...

    Abstract Background: The purpose of this study was to assess the prognostic effect of coronary collaterals on early and midterm clinical outcomes in patients undergoing first time isolated off-pump coronary artery bypass (OPCAB) surgery.
    Methods: Preoperative angiograms from 861 patients were evaluated to assess the presence and extent of coronary collaterals (Rentrop classification). Coronary collaterals (CC) were present in 485 (56.3%) patients (CC group). Patients with coronary collaterals had a higher incidence of preoperative myocardial infarction, lower ejection fraction, and higher Parsonnet scores compared with patients without coronary collaterals (no-CC group).
    Results: Coronary collaterals were associated with myocardial protection during OPCAB surgery, as evidenced by a significantly lower incidence of intraoperative ST-segment changes (propensity matched cohort, p = 0.008). No other statistically significant differences in in-hospital outcomes were detected between the two groups. Five years after surgery patient survival was 84.8% (95% confidence interval [CI] 79.4 to 88.8) in the CC group compared with 89.2% (95% CI 84.4 to 92.6) in the no-CC group (p = 0.48). Cardiac-related event-free survival after 5 years was 50.6% (95% CI 43.5 to 57.3) in the CC group and 54.5% (95% CI 47.1 to 61.4) in the no-CC group (p = 0.96), with no significant differences between both groups, before or after risk adjustment, or when comparing propensity-matched cohort.
    Conclusions: Although patients with coronary collaterals had more extensive coronary artery disease, poor left ventricular function, and more cardiac risk factors than patients without collaterals, the early and midterm clinical outcome after OPCAB surgery was comparable between the two groups.
    MeSH term(s) Aged ; Case-Control Studies ; Collateral Circulation/physiology ; Confidence Intervals ; Coronary Angiography ; Coronary Artery Bypass, Off-Pump/methods ; Coronary Artery Bypass, Off-Pump/mortality ; Coronary Circulation/physiology ; Coronary Disease/diagnostic imaging ; Coronary Disease/mortality ; Coronary Disease/surgery ; Female ; Follow-Up Studies ; Heart Function Tests ; Humans ; Male ; Middle Aged ; Myocardial Ischemia/prevention & control ; Probability ; Proportional Hazards Models ; Retrospective Studies ; Risk Assessment ; Stroke Volume ; Survival Analysis ; Time Factors ; Treatment Outcome
    Language English
    Publishing date 2008-01
    Publishing country Netherlands
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 211007-6
    ISSN 1552-6259 ; 0003-4975
    ISSN (online) 1552-6259
    ISSN 0003-4975
    DOI 10.1016/j.athoracsur.2007.08.026
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 252: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Clinical and Prognostic Factors in Patients with IgG4-Related Kidney Disease.

    Chaba, Anis / Devresse, Arnaud / Audard, Vincent / Boffa, Jean Jacques / Karras, Alexandre / Cartery, Claire / Deltombe, Clément / Chemouny, Jonathan / Contamin, Claudine / Courivaud, Cecile / Duquennoy, Simon / Garcia, Hugo / Joly, Dominique / Goumri, Nabila / Hanouna, Guillaume / Halimi, Jean Michel / Plaisier, Emmanuelle / Hamidou, Mohamed / Landron, Cédric /
    Launay, David / Lebas, Celine / Legendre, Mathieu / Masseau, Agathe / Mathian, Alexis / Mercadal, Lucile / Morel, Nathalie / Mutinelli-Szymanski, Prisca / Palat, Sylvain / Pennaforte, Jean-Loup / Peraldi, Marie Noelle / Pozdzik, Agnieszka / Schleinitz, Nicolas / Thaunat, Olivier / Titeca-Beauport, Dimitri / Mussini, Charlotte / Touati, Sonia / Prinz, Eric / Faller, Anne Laure / Richter, Sarah / Vilaine, Eve / Ferlicot, Sophie / Von-Kotze, Clarissa / Belliere, Julie / Olagne, Jerome / Mesbah, Rafik / Snanoudj, Renaud / Nouvier, Mathilde / Ebbo, Mikael / Zaidan, Mohamad

    Clinical journal of the American Society of Nephrology : CJASN

    2023  Volume 18, Issue 8, Page(s) 1031–1040

    Abstract: Background: IgG4-related kidney disease is a major manifestation of IgG4-related disease, a systemic fibroinflammatory disorder. However, the clinical and prognostic kidney-related factors in patients with IgG4-related kidney disease are insufficiently ... ...

    Abstract Background: IgG4-related kidney disease is a major manifestation of IgG4-related disease, a systemic fibroinflammatory disorder. However, the clinical and prognostic kidney-related factors in patients with IgG4-related kidney disease are insufficiently defined.
    Methods: We conducted an observational cohort study using data from 35 sites in two European countries. Clinical, biologic, imaging, and histopathologic data; treatment modalities; and outcomes were collected from medical records. Logistic regression was performed to identify the possible factors related to an eGFR ≤30 ml/min per 1.73 m 2 at the last follow-up. Cox proportional hazards model was performed to assess the factors associated with the risk of relapse.
    Results: We studied 101 adult patients with IgG4-related disease with a median follow-up of 24 (11-58) months. Of these, 87 (86%) patients were male, and the median age was 68 (57-76) years. Eighty-three (82%) patients had IgG4-related kidney disease confirmed by kidney biopsy, with all biopsies showing tubulointerstitial involvement and 16 showing glomerular lesions. Ninety (89%) patients were treated with corticosteroids, and 18 (18%) patients received rituximab as first-line therapy. At the last follow-up, the eGFR was below 30 ml/min per 1.73 m 2 in 32% of patients; 34 (34%) patients experienced a relapse, while 12 (13%) patients had died. By Cox survival analysis, the number of organs involved (hazard ratio [HR], 1.26; 95% confidence interval [CI], 1.01 to 1.55) and low C3 and C4 concentrations (HR, 2.31; 95% CI, 1.10 to 4.85) were independently associated with a higher risk of relapse, whereas first-line therapy with rituximab was protective (HR, 0.22; 95% CI, 0.06 to 0.78). At their last follow-up, 19 (19%) patients had an eGFR ≤30 ml/min per 1.73 m 2 . Age (odd ratio [OR], 1.11; 95% CI, 1.03 to 1.20), peak serum creatinine (OR, 2.74; 95% CI, 1.71 to 5.47), and serum IgG4 level ≥5 g/L (OR, 4.46; 95% CI, 1.23 to 19.40) were independently predictive for severe CKD.
    Conclusions: IgG4-related kidney disease predominantly affected middle-aged men and manifested as tubulointerstitial nephritis with potential glomerular involvement. Complement consumption and the number of organs involved were associated with a higher relapse rate, whereas first-line therapy with rituximab was associated with lower relapse rate. Patients with high serum IgG4 concentrations (≥5 g/L) had more severe kidney disease.
    MeSH term(s) Adult ; Middle Aged ; Humans ; Male ; Aged ; Female ; Immunoglobulin G4-Related Disease/complications ; Immunoglobulin G4-Related Disease/diagnosis ; Immunoglobulin G4-Related Disease/drug therapy ; Rituximab/adverse effects ; Cohort Studies ; Prognosis ; Kidney/pathology ; Nephritis, Interstitial/pathology ; Immunoglobulin G ; Recurrence ; Retrospective Studies
    Chemical Substances Rituximab (4F4X42SYQ6) ; Immunoglobulin G
    Language English
    Publishing date 2023-06-07
    Publishing country United States
    Document type Observational Study ; Journal Article
    ZDB-ID 2226665-3
    ISSN 1555-905X ; 1555-9041
    ISSN (online) 1555-905X
    ISSN 1555-9041
    DOI 10.2215/CJN.0000000000000193
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6584: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article: 46th Medical Maghrebian Congress. November 9-10, 2018. Tunis.

    Alami Aroussi, A / Fouad, A / Omrane, A / Razzak, A / Aissa, A / Akkad, A / Amraoui, A / Aouam, A / Arfaoui, A / Belkouchi, A / Ben Chaaben, A / Ben Cheikh, A / Ben Khélifa, A / Ben Mabrouk, A / Benhima, A / Bezza, A / Bezzine, A / Bourrahouat, A / Chaieb, A /
    Chakib, A / Chetoui, A / Daoudi, A / Ech-Chenbouli, A / Gaaliche, A / Hassani, A / Kassimi, A / Khachane, A / Labidi, A / Lalaoui, A / Masrar, A / McHachi, A / Nakhli, A / Ouakaa, A / Siati, A / Toumi, A / Zaouali, A / Condé, A Y / Haggui, Abdeddayem / Belaguid, Abdelaziz / El Hangouche, Abdelkader Jalil / Gharbi, Abdelkarim / Mahfoudh, Abdelmajid / Bouzouita, Abderrazek / Aissaoui, Abir / Ben Hamouda, Abir / Hedhli, Abir / Ammous, Adel / Bahlous, Afef / Ben Halima, Afef / Belhadj, Ahlem / Bezzine, Ahlem / Blel, Ahlem / Brahem, Ahlem / Banasr, Ahmed / Meherzi, Ahmed / Saadi, Ahmed / Sellami, Ahmed / Turki, Ahmed / Ben Miled, Aicha / Ben Slama, Aida / Daib, Aida / Zommiti, Alaa / Chadly, Ali / Jmaa, Ali / Mtiraoui, Ali / Ksentini, Alia / Methnani, Alia / Zehani, Alya / Kessantini, Amal / Farah, Amani / Mankai, Amani / Mellouli, Amani / Zaouali, Amani / Touil, Amany / Hssine, Ameni / Ben Safta, Amine / Derouiche, Amine / Jmal, Amine / Ferjani, Amir / Djobbi, Amira / Dridi, Amira / Aridhi, Amna / Bahdoudi, Anis / Ben Amara, Anis / Benzarti, Anis / Ben Slama, Anouar Youssef / Oueslati, Anouer / Soltani, Aouatef / Chadli, Aschraf / Aloui, Asma / Belghuith Sriha, Asma / Bouden, Asma / Laabidi, Asma / Mensi, Asma / Ouakaa, Asma / Sabbek, Asma / Zribi, Asma / Green, Assia / Ben Nasr, Atef / Azaiez, Aymen / Yeades, Aza / Belhaj, Azza / Mediouni, Azza / Sammoud, Azza / Slim, Azza / Amine, B / Chelly, B / Jatik, B / Lmimouni, B / Daouahi, Bachir / Ben Khelifa, Badereddine / Louzir, Bechir / Dorra, Ali / Dhahri, Besma / Ben Nasrallah, C / Chefchaouni, C / Konzi, C / Loussaief, C / Makni, C / Dziri, Chadli / Bouguerra, Chaker / Kays, Chaker / Zedini, Chekib / Dhouha, Cherif / Mohamed, Cherif / Aichaouia, Chiraz / Dhieb, Chiraz / Fofana, D / Gargouri, Dalila / Chebil, Dhekra / Issaoui, Dhilel / Gouiaa, Donia / Brahim, Dorra / Essid, Dorra / Jarraya, Dorra / Trad, Dorra / Ben Hmida, E / Sboui, E / Ben Brahim, Ehsen / Baati, Elyes / Talbi, Emna / Chaari, Eya / Hammami, Eya / Ghazouani, Ezzeddine / Ayari, F / Ben Hariz, F / Bennaoui, F / Chebbi, F / Chigr, F / Guemira, F / Harrar, F / Benmoula, F Z / Ouali, F Z / Maoulainine, F M R / Bouden, Faten / Fdhila, Faten / Améziani, Fatiha / Bouhaouala, Fatma / Charfi, Fatma / Chermiti Ben Abdallah, Fatma / Hammemi, Fatma / Jarraya, Fatma / Khanchel, Fatma / Ourda, Fatma / Sellami, Fatma / Trabelsi, Fatma / Yangui, Ferdaous / Fekih Romdhane, Feten / Mellouli, Fethi / Nacef Jomli, Fethi / Mghaieth, Fethia / Draiss, G / Elamine, G / Kablouti, G / Touzani, G / Manzeki, G B / Garali, Ghada / Drissi, Ghassen / Besbes, Ghazi / Abaza, H / Azzouz, H / Said Latiri, H / Rejeb, H / Ben Ammar, H / Ben Brahim, H / Ben Jeddi, H / Ben Mahjouba, H / Besbes, H / Dabbebi, H / Douik, H / El Haoury, H / Elannaz, H / Elloumi, H / Hachim, H / Iraqi, H / Kalboussi, H / Khadhraoui, H / Khouni, H / Mamad, H / Metjaouel, H / Naoui, H / Zargouni, H / Elmalki, H O / Feki, Habib / Haouala, Habib / Jaafoura, Habib / Drissa, Habiba / Mizouni, Habiba / Kamoun, Hager / Ouerda, Haifa / Zaibi, Haifa / Chiha, Haithem / Kamoun, Hajer / Saibi, Hajer / Skhiri, Hajer / Boussaffa, Hamza / Majed, Hamza / Blibech, Hana / Daami, Hana / Harzallah, Hana / Rkain, Hanan / Ben Massoud, Hanen / Jaziri, Hanene / Ben Said, Hanène / Ayed, Haroun / Harrabi, Hassen / Chaabouni, Hatem / Ladida Debbache, Hayet / Harbi, Hayett / Yacoub, Haythem / Abroug, Hela / Ghali, Hela / Kchir, Hela / Msaad, Hela / Ghali, Héla / Manai, Héla / Riahi, Hend / Bousselmi, Hiba / Limem, Hiba / Aouina, Hichem / Jerraya, Hichem / Ben Ayed, Houda / Chahed, Houda / Snéne, Houda / Lahlou Amine, I / Nouiser, I / Ait Sab, I / Chelly, I / Elboukhani, I / Ghanmi, I / Kallala, I / Kooli, I / Bouasker, Ibtissem / Fetni, Ilhem / Bachouch, Imen / Bouguecha, Imen / Chaabani, Imen / Gazzeh, Imen / Samaali, Imen / Youssef, Imen / Zemni, Imen / Bachouche, Imene / Youssef, Imène / Bouannene, Ines / Kasraoui, Ines / Laouini, Ines / Mahjoubi, Ines / Maoudoud, Ines / Riahi, Ines / Selmi, Ines / Tka, Ines / Hadj Khalifa, Islem / Mejri, Islem / Béjia, Ismail / Bellagha, J / Boubaker, Jallel / Daghfous, Jalloul / Dammak, Jamel / Hleli, Jamila / Ben Amar, Jihen / Jedidi, Jihen / Marrakchi, Jihen / Kaoutar, K / Arjouni, K / Ben Helel, K / Benouhoud, K / Rjeb, K / Imene, Kacem / Samoud, Kais / El Jeri, Kaouther / Abid, Karem / Chaker, Kays / Abid, Khadija / Bouzghaîa, Khadija / Kamoun, Khaled / Zitouna, Khaled / Oughlani, Khalil / Lassoued, Khaoula / Letaif, Khaoula / Hakim, Khaouther / Cherif Alami, L / Benhmidoune, L / Boumhil, L / Bouzgarrou, L / Dhidah, L / Ifrine, L / Kallel, Lamia / Merzougui, Latifa / Errguig, Leila / Mouelhi, Leila / Sahli, Lina / Maoua, M / Rejeb, M / Ben Rejeb, M / Bouchrik, M / Bouhoula, M / Bourrous, M / Bouskraoui, M / El Belhadji, M / Essakhi, M / Essid, M / Gharbaoui, M / Haboub, M / Iken, M / Krifa, M / Lagrine, M / Leboyer, M / Najimi, M / Rahoui, M / Sabbah, M / Sbihi, M / Zouine, M / Chefchaouni, M C / Gharbi, M H / El Fakiri, M M / Tagajdid, M R / Shimi, Maha / Touaibia, Maha / Jguirim, Mahbouba / Barsaoui, Maher / Belghith, Maissa / Ben Jmaa, Maissa / Koubaa, Makram / Tbini, Makram / Boughdir, Malak / Ben Salah, Mamia / Ben Fraj, Manel / Ben Halima, Manel / Ben Khalifa, Manel / Bousleh, Manel / Limam, Manel / Mabrouk, Manel / Mallouli, Manel / Rebeii, Manel / Ayari, Mariem / Belhadj, Mariem / Ben Hmida, Mariem / Boughattas, Mariem / Drissa, Mariem / El Ghardallou, Mariem / Fejjeri, Mariem / Hamza, Mariem / Jaidane, Mariem / Jrad, Mariem / Kacem, Mariem / Mersni, Mariem / Mjid, Mariem / Sabbah, Mariem / Serghini, Mariem / Triki, Mariem / Ben Abbes, Maroua / Boussaid, Maroua / Gharbi, Maroua / Hafi, Maroua / Slama, Maroua / Trigui, Maroua / Taoueb, Marouen / Chakroun, Marouene / Ben Cheikh, Marwa / Chebbi, Marwa / Hadj Taieb, Marwa / Kacem, Marwa / Ben Khelil, Mehdi / Hammami, Mehdi / Khalfallah, Mehdi / Ksiaa, Mehdi / Mechri, Mehdi / Mrad, Mehdi / Sboui, Mehdi / Bani, Mejda / Hajri, Melek / Mellouli, Menel / Allouche, Mohamed / Mesrati, Mohamed Amine / Mseddi, Mohamed Amine / Amri, Mohamed / Bejaoui, Mohamed / Bellali, Mohamed / Ben Amor, Mohamed / Ben Dhieb, Mohamed / Ben Moussa, Mohamed / Chebil, Mohamed / Cherif, Mohamed / Fourati, Mohamed / Kahloul, Mohamed / Khaled, Mohamed / Machghoul, Mohamed / Mansour, Mohamed / Abdesslem, Mohamed Morched / Ben Chehida, Mohamed Ali / Chaouch, Mohamed Ali / Essid, Mohamed Ali / Meddeb, Mohamed Ali / Gharbi, Mohamed Chawki / Elleuch, Mohamed Habib / Loueslati, Mohamed Hédi / Sboui, Mohamed Mehdi / Mhiri, Mohamed Nabil / Kilani, Mohamed Osman / Ben Slama, Mohamed Riadh / Charfi, Mohamed Ridha / Nakhli, Mohamed Said / Mourali, Mohamed Sami / El Asli, Mohamed Selim / Lamouchi, Mohamed Taher / Cherti, Mohammed / Khadhraoui, Mohsen / Bibi, Mokhtar / Hamdoun, Moncef / Kassis, Mondher / Touzi, Mongi / Ben Khaled, Monia / Fekih, Monia / Khemiri, Monia / Ouederni, Monia / Hchicha, Monjia / Kassis, Monther / Ben Attia, Mossadak / Yahyaoui, Moufida / Ben Azaiez, Mouna / Bousnina, Mouna / Ben Jemaa, Mounir / Ben Yahia, Mounir / Daghfous, Mounir / Haj Slimen, Mourad / Assidi, Msadak / Belhadj, N / Ben Mustapha, N / El Idrissislitine, N / Hikki, N / Kchir, N / Mars, N / Meddeb, N / Ouni, N / Rada, N / Rezg, N / Trabelsi, N / Bouafia, Nabiha / Haloui, Nabil / Benfenatki, Nacéra / Bergaoui, Naceur / Yomn, Naceur / Ben Mustapha, Nadia / Maamouri, Nadia / Mehiri, Nadia / Siala, Nadia / Beltaief, Najeh / Aridhi, Najet / Sidaoui, Najet / Walid, Najia / Mechergui, Najla / Mnif, Najla / Ben Chekaya, Nariméne / Bellil, Nawel / Dhouib, Nawel / Achour, Nazek / Kaabar, Nejib / Mrizak, Nejib / Mnif, Nejla / Chaouech, Nesrine / Hasni, Nesrine / Issaoui, Nesrine / Ati, Nidhal / Balloumi, Nidhal / Haj Salem, Nidhal / Ladhari, Nizar / Akif, Nora / Liani, Nora / Hajji, Nouha / Trad, Nouha / Elleuch, Nour / Marzouki, Nour El Houda / Larbi, Noureddine / M'barek, Nourelhouda / Rebai, Nouri / Bibani, Noursaf / Ben Salah, Nozha / Belmaachi, O / Elmaalel, O / Jlassi, O / Mihoub, O / Ben Zaid, Olfa / Bouallègue, Olfa / Bousnina, Olfa / Bouyahia, Olfa / El Maalel, Olfa / Fendri, Omar / Azzabi, Ons / Borgi, Ons / Ghdes, Ons / Ben Rejeb, Oussama / Rachid, R / Abi, R / Bahiri, R / Boulma, R / Elkhayat, R / Habbal, R / Tamouza, R / Jomli, Rabaa / Ben Abdallah, Rabiaa / Smaoui, Racha / Debbeche, Radhouene / Fakhfakh, Radhouene / El Kamel, Rafik / Gargouri, Rahma / Jouini, Raja / Nouira, Ramzi / Fessi, Rana / Bannour, Rania / Ben Rabeh, Rania / Kacem, Rania / Khmakhem, Rania / Ben Younes, Raouf / Karray, Raouf / Cheikh, Rezaik / Ben Malek, Riadh / Ben Slama, Ridha / Kouki, Ridha / Baati, Rim / Bechraoui, Rim / Fakhfakh, Rim / Fradi, Rim / Lahiani, Rim / Ridha, Rim / Zainine, Rim / Kallel, Roua / Rostom, S / Ben Abdallah, S / Ben Hammamia, S / Benchérifa, S / Benkirane, S / Chatti, S / El Guedri, S / El Oussaoui, S / Elkochri, S / Elmoussaoui, S / Enbili, S / Gara, S / Haouet, S / Khammeri, S / Khefecha, S / Khtrouche, S / Macheghoul, S / Mallouli, S / Rharrit, S / Skouri, S / Helali, Saan / Boulehmi, Sabrine / Abid, Sahar / Naouar, Sahbi / Zelfani, Saida / Ben Amar, Salah / Ajmi, Salem / Braiek, Salem / Yahiaoui, Salem / Ghezaiel, Salima / Ben Toumia, Salma / Thabeti, Salma / Daboussi, Salsabil / Ben Abderahman, Salwa / Rhaiem, Samar / Ben Rhouma, Sami / Rekaya, Samia / Haddad, Samir / Kammoun, Samir / Merai, Samira / Mhamdi, Samira / Ben Ali, Rabaa / Gaaloul, Sana / Ouali, Sana / Taleb, Sana / Zrour, Saoussen / Hamdi, Sarah / Zaghdoudi, Sarah / Ammari, Sarra / Ben Abderrahim, Sarra / Karaa, Sarra / Maazaoui, Sarra / Saidani, Sarra / Stambouli, Sarra / Mokadem, Seif / Boudiche, Selim / Zaghbib, Selim / Ayedi, Shema / Jardek, Sinda / Bouselmi, Siwar / Chtourou, Sonda / Manoubi, Sondos / Bahri, Sonia / Halioui, Sonia / Jrad, Sonia / Mazigh, Sonia / Ouerghi, Sonia / Toujani, Sonia / Fenniche, Soraya / Aboudrar, Souad / Meriem Amari, Souad / Karouia, Souhaiel / Bourgou, Soumaya / Halayem, Soumaya / Rammeh, Soumaya / Yaïch, Sourour / Ben Nasrallah, Syrine / Chouchane, Syrine / Ftini, Syrine / Makni, Syrine / Manoubi, Syrine / Miri, Syrine / Saadi, Syrine / Manoubi, Syrine Azza / Khalfallah, T / Mechergui, Takwa / Dakka, Taoufiq / Barhoumi, Tarek / M'rad, Tej El Baha / Ajmi, Thouraya / Dorra, Trad / Ouali, Uta / Hannachi, W / Ferjaoui, Wael / Aissi, Wafa / Dahmani, Wafa / Dhouib, Wafa / Koubaa, Wafa / Zhir, Wafa / Gheriani, Wafe / Arfa, Wajdi / Dougaz, Wajih / Sahnoun, Wajih / Naija, Walid / Sami, Y / Bouteraa, Y / Elhamdaoui, Y / Hama, Y / Ouahchi, Yacine / Guebsi, Yassine / Nouira, Yassine / Daly, Yosr / Mahjoubi, Yosra / Mejdoub, Yosra / Mosbahi, Yosra / Said, Yosra / Zaimi, Yosra / Zgueb, Yosra / Dridi, Yousr / Mesbahi, Yousra / Gharbi, Youssef / Hellal, Youssef / Hechmi, Z / Zid, Z / Elmouatassim, Z / Ghorbel, Z / Habbadi, Z / Marrakchi, Zahra / Hidouri, Zaki / Abbes, Zeineb / Ouhachi, Zeineb / Khessairi, Zied / Khlayfia, Zied / Mahjoubi, Zied / Moatemri, Zied

    La Tunisie medicale

    2019  Volume 97, Issue 1, Page(s) 177–258

    MeSH term(s) Africa, Northern/epidemiology ; Anatomy/education ; Education, Medical/history ; Education, Medical/methods ; Education, Medical/organization & administration ; Education, Medical/trends ; History, 21st Century ; Humans ; Internship and Residency/standards ; Internship and Residency/trends ; Job Satisfaction ; Medicine/methods ; Medicine/organization & administration ; Medicine/trends ; Pathology, Clinical/education ; Tunisia/epidemiology
    Language English
    Publishing date 2019-09-20
    Publishing country Tunisia
    Document type Congress ; Historical Article
    ZDB-ID 128627-4
    ISSN 0041-4131
    ISSN 0041-4131
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 223: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Poster abstracts of the 4th Congress of Tunisian Society of Oncology Radiotherapy (STOR). November 2018.

    Kallel, Adel / Khanfir, Afef / Jmal, Aida / Essadok, Ali / Khalfallah, Ali / Boussarsar, Amal / Chamsi, Amal / Yousfi, Amani / Mezlini, Amel / Hdiji, Anis / Moalla, Anis / Mtibaa, Anis / Belaïd, Asma / Ghorbel, Asma / Hadhri, Asma / Hamdoun, Awatef / Oualha, Azhar / Keskes, Aïcha / Graja Ben Cheikha, Besma /
    Daoud, Bilel / Hammemi, Bouthaina / Zaidi, Chaker / Ben Ammar, Chiraz / Nasr, Chiraz / Yazid, Dalia / Daoud, Jamel / Zaidi, Emna / Dhouib, Fatma / Elloumi, Fatma / Noubbigh, Ghaiet El Fida / Jaffel, Hager / Abdelhédi, Hajer / Kammoun, Hajer / Ouaz, Hamza / Bensalah, Hanène / Njeh, Hanène / Daoud, Hend / Abdelatif, Imen / Chabchoub, Imène / Chaffai, Ines / Werda, Ines / Saidani, Intidhar / Naceur, Islem / Yahiaoui, Jamel / Chaabène, Kais / Khabir, Abdelmajid / Ben Zid, Khadija / Meddeb, Khadija / Ben Fradj, Khalil / Mahjoubi, Khalil / Meddeb, Khedija / Ben Mahfoudh, Kheireddine / Farhat, Leila / Ghorbal, Lilia / Mrissa, Linda / Ben Salem, Lotfi / Kochbati, Lotfi / Jebsi, Manel / Bohli, Mariem / Bouhamed, Maroua / Mahdouani, Marouen / Fourati, Mohamed / Morroka, K / Ben Rejeb, Mouna / Kallel, Mouna / Besbes, Mounir / Toumi, Nabil / Neifar, Nada / Bouzid, Nadia / Nsiri, Nadia / Tounsi, Nadra / Fourati, Najla / Gouiaa, Naourez / Absi, Narjes / Chaari, Narjes / Fourati, Nejla / Bouaouina, Noureddine / Toumi, Nozha / Kammoun, Omar / Nouri, Omar / Braikia, Radhouane / Mzali, Rafik / Ben Amor, Raouia / Abidi, Rim / Moujahed, Rim / Trigui, Rim / Meftah, Sabrine / Tbessi, Sabrine / Boughanmi, Safa / Yahyaoui, Safia / Gritli, Said / Soltani, Said / Tebra, Sameh / Tebra Mrad, Sameh / Kannoun Belajouza, Samia / Kanoun, Samia / Gamra, Sana / Saghaier, Sarra / Zaraa, Semia / Zouari, Sirine / Kdous, Skander / Haddar, Sondes / Ben Dhia, Syrine / Sghaier, Syrine / Boudawara, Taheya / Sahnoun, Tarak / Salem Zrafi, Wael / Mnejja, Wafa / Ben Kridis, Wala / Gargouri, Walid / Siala, Wicem / Abid, Wiem / Boudawara, Zaher / Fessi, Zied

    La Tunisie medicale

    2019  Volume 96, Issue 12, Page(s) 911–931

    MeSH term(s) Congresses as Topic ; Female ; Head and Neck Neoplasms/pathology ; Head and Neck Neoplasms/radiotherapy ; Humans ; Male ; Medical Oncology/methods ; Medical Oncology/organization & administration ; Medical Oncology/trends ; Organs at Risk ; Radiation Oncology/methods ; Radiation Oncology/organization & administration ; Radiation Oncology/standards ; Radiation Oncology/trends ; Radiotherapy Dosage ; Societies, Medical/organization & administration ; Societies, Medical/standards ; Tunisia
    Language English
    Publishing date 2019-05-27
    Publishing country Tunisia
    Document type Congress
    ZDB-ID 128627-4
    ISSN 0041-4131
    ISSN 0041-4131
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 223: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top